KANTAR HEALTH BLOG

kh_blog_hero_1600px
  • Oncology Conference Insight: ASCO 2016 --- The pace of treatment in metastatic melanoma has significantly accelerated in the past couple of years. What was once a disease beset by toxic and largely ineffective treatments now enjoys a number of effective agents that have reduced the mortality of this aggressive disease.
  • CASTOR Shines in Relapsed/Refractory Multiple Myeloma

    by Jay Grisolano  |  Jun 5, 2016
    Oncology Conference Insight: ASCO 2016 --- The armamentarium of treatment options available for patients with multiple myeloma continues to grow as the result of several recent, successful novel therapeutic agents in development.
  • VYXEOS scores a 10 over 7+3

    by Stephanie Hawthorne  |  Jun 4, 2016
    Oncology Conference Insight: ASCO 2016 --- Therapeutic approaches for acute myeloid leukemia (AML) have gone unchanged for several years. Most newly diagnosed patients achieve complete remission (CR) with a combination regimen of cytarabine plus an anthracycline (7+3 most commonly). However, the high rate of CR comes at the cost of a high level of toxicities with this regimen.
  • Understanding Life with Chronic Pain

    by Brian Mondry  |  Jun 2, 2016
    When seeking to understand the patient experience, we must connect with the emotional toll of quality-of-life issues.
  • Smoking has been associated with status and glamor, but nowadays the social perception of tobacco use has changed. This can be noted in the decrease in the number of smokers around the world, but the World Health Organization (WHO) aims at reducing this rate even further: the goal is to decrease by 30% the number of smokers until 2025.
© 2017 Kantar Health, A Kantar Company